A chronic course of angiogenic blockade in either YKL-40 or VEGF may not receive a full elimination of tumor angiogenesis; instead, an unexpected compensation by the other factor may lead to an opposite outcome including resistance to the single-factor treatment and angiogenic rebound. This evidence concerns the gene VEGFA and neoplasm.